A detailed history of Anderson Hoagland & CO transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Anderson Hoagland & CO holds 28,967 shares of GILD stock, worth $3.59 Million. This represents 0.32% of its overall portfolio holdings.

Number of Shares
28,967
Holding current value
$3.59 Million
% of portfolio
0.32%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 05, 2026

BUY
$110.56 - $125.2 $3.2 Million - $3.63 Million
28,967 New
28,967 $3.59 Million
Q1 2020

Apr 23, 2020

SELL
$62.63 - $80.22 $715,234 - $916,112
-11,420 Closed
0 $0
Q2 2019

Jul 03, 2019

SELL
$61.87 - $69.38 $997,344 - $1.12 Million
-16,120 Reduced 58.53%
11,420 $711,000
Q1 2018

Apr 24, 2018

SELL
$72.84 - $88.8 $296,823 - $361,860
-4,075 Reduced 12.89%
27,540 $2.08 Million
Q3 2017

Oct 17, 2017

BUY
$72.11 - $85.47 $2.28 Million - $2.7 Million
31,615
31,615 $2.56 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $156B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Anderson Hoagland & CO Portfolio

Follow Anderson Hoagland & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Anderson Hoagland & CO, based on Form 13F filings with the SEC.

News

Stay updated on Anderson Hoagland & CO with notifications on news.